AU2015229222C1 - Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders - Google Patents

Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders Download PDF

Info

Publication number
AU2015229222C1
AU2015229222C1 AU2015229222A AU2015229222A AU2015229222C1 AU 2015229222 C1 AU2015229222 C1 AU 2015229222C1 AU 2015229222 A AU2015229222 A AU 2015229222A AU 2015229222 A AU2015229222 A AU 2015229222A AU 2015229222 C1 AU2015229222 C1 AU 2015229222C1
Authority
AU
Australia
Prior art keywords
fxa
fii
composition
concentration
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015229222A
Other languages
English (en)
Other versions
AU2015229222B2 (en
AU2015229222A1 (en
Inventor
Michael Dockal
Sabine KNAPPE
Friedrich Scheiflinger
Susanne Till
Peter Leopold Turecek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52727470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015229222(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2015229222A1 publication Critical patent/AU2015229222A1/en
Publication of AU2015229222B2 publication Critical patent/AU2015229222B2/en
Application granted granted Critical
Publication of AU2015229222C1 publication Critical patent/AU2015229222C1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2015229222A 2014-03-14 2015-03-13 Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders Active AU2015229222C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953496P 2014-03-14 2014-03-14
US61/953,496 2014-03-14
PCT/US2015/020361 WO2015138847A1 (en) 2014-03-14 2015-03-13 Compositions of human prothrombin and activated factor x for improving hemostasis in the treatment of bleeding disorders

Publications (3)

Publication Number Publication Date
AU2015229222A1 AU2015229222A1 (en) 2016-09-29
AU2015229222B2 AU2015229222B2 (en) 2020-08-27
AU2015229222C1 true AU2015229222C1 (en) 2020-12-24

Family

ID=52727470

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015229222A Active AU2015229222C1 (en) 2014-03-14 2015-03-13 Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders

Country Status (9)

Country Link
US (2) US20150258182A1 (enExample)
EP (1) EP3116534B1 (enExample)
JP (1) JP6535036B2 (enExample)
CN (1) CN106413744B (enExample)
AU (1) AU2015229222C1 (enExample)
ES (1) ES2742898T3 (enExample)
NZ (1) NZ724105A (enExample)
TW (1) TWI653047B (enExample)
WO (1) WO2015138847A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI653047B (zh) 2014-03-14 2019-03-11 百特製藥公司 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物
JP7227905B2 (ja) 2017-02-09 2023-02-22 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血の処置または予防における使用のための血液凝固因子代替製品
EP3590528A1 (en) * 2018-07-06 2020-01-08 Octapharma AG Fx activation process and its use in the preparation of a fxa composition
MX2024008243A (es) 2021-12-30 2024-09-04 Baxter Int Soluciones de fibrinogeno y trombina para un sellador de fibrina y un kit de sellador de fibrina.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866122A (en) * 1996-03-20 1999-02-02 Immuno Aktiengesellschaft Pharmaceutical preparation for treating blood coagulation disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287180A (en) 1980-01-28 1981-09-01 Baxter Travenol Laboratories, Inc. Method for treating blood clotting factor inhibitors
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
CA2790248A1 (en) * 2010-03-15 2011-09-22 Ferrosan Medical Devices A/S A method for promotion of hemostasis and/or wound healing
TWI653047B (zh) 2014-03-14 2019-03-11 百特製藥公司 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866122A (en) * 1996-03-20 1999-02-02 Immuno Aktiengesellschaft Pharmaceutical preparation for treating blood coagulation disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P L Turecek ET AL, "FEIBA: mode of action", Haemophilia : the official journal of the World Federation of Hemophilia, England, (2004-09-01), page 3, URL: http://www.ncbi.nlm.nih.gov/pubmed/15385040 *

Also Published As

Publication number Publication date
AU2015229222B2 (en) 2020-08-27
TW201620545A (zh) 2016-06-16
US20190231855A1 (en) 2019-08-01
JP2017508806A (ja) 2017-03-30
EP3116534A1 (en) 2017-01-18
ES2742898T3 (es) 2020-02-17
TWI653047B (zh) 2019-03-11
JP6535036B2 (ja) 2019-06-26
WO2015138847A1 (en) 2015-09-17
AU2015229222A1 (en) 2016-09-29
CN106413744B (zh) 2020-09-04
US20150258182A1 (en) 2015-09-17
CN106413744A (zh) 2017-02-15
US11160850B2 (en) 2021-11-02
NZ724105A (en) 2023-02-24
EP3116534B1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
Göb et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation
Levy et al. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy
US11160850B2 (en) Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders
US7425539B2 (en) Factor IXa for the treatment of bleeding disorders
Ross et al. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency
Federici et al. Clinical efficacy of highly purified, doubly virus‐inactivated factor VIII/von Willebrand factor concentrate (Fanhdi®) in the treatment of von Willebrand disease: a retrospective clinical study
PT1344533E (pt) Composições farmacêuticas compreendendo lectina de ligação a manose
AU2010355558A1 (en) Treatment of coagulopathy with hyperfibrinolysis
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
BR112014004297B1 (pt) Uso de um inibidor de antitrombina iii no tratamento ou prevenção de sangramento
CA2934081A1 (en) Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof
Ovanesov et al. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution
Ross et al. Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia
KR102302688B1 (ko) 혈전성 혈소판감소성 자반 치료 약물 제조에서의 항혈소판 트롬볼리신의 응용
Valerieva et al. Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema
JP2018509398A (ja) Ｃ１エステラーゼ阻害剤の医薬製剤
Arun et al. Clotting Factor Concentrates
Nowak-Göttl et al. Replacement therapy in patients with von Willebrand disease—indications and monitoring
CN102481344A (zh) 具有纤溶亢进的凝血病的治疗
KR20190111912A (ko) 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품
US20170042981A1 (en) Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor
Shusterman et al. Transfusion of the patient with congenital coagulation defects
EP2961422A1 (en) Therapeutic agent for amniotic fluid embolism
JP2007055899A (ja) 血液凝固第ｘ因子を主剤とする血液凝固異常に基づく疾患の治療・予防用医薬組成物
JP2020508963A (ja) Ｒｍｐ組成物および使用方法

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 SEP 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 07 SEP 2020

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): BAXALTA GMBH; BAXALTA INCORPORATED